...
首页> 外文期刊>ChemMedChem >Progress in the Development of Platelet-Activating Factor Receptor (PAFr) Antagonists and Applications in the Treatment of Inflammatory Diseases
【24h】

Progress in the Development of Platelet-Activating Factor Receptor (PAFr) Antagonists and Applications in the Treatment of Inflammatory Diseases

机译:血小板活化因子受体(PAFR)拮抗剂和应用在治疗炎症性疾病中的进展

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Platelet-activating factor (PAF) and its receptor (PAFr) have been implicated in a wide range of diseases and disorders that originate from the activation of inflammatory pathways. Although the exact structure of the binding site on the PAFr remains unknown, the PAFr is a well-established therapeutic target, and an array of structurally diverse PAFr antagonists have been identified. These include compounds that are structurally similar to the natural PAF ligand, synthetic heterocycles, complex polycyclic natural products, and various metal complexes. This review provides an update on more than 20 years of progress in this area. The development and synthesis of new PAFr antagonists, structure-activity relationship studies, the biological activity of these molecules, and their therapeutic potential are discussed.
机译:血小板激活因子(PAF)及其受体(PAFR)涉及来自源自炎症途径的各种疾病和疾病。 虽然PAFR上的结合位点的确切结构仍然未知,但PAFR是一种良好的治疗靶标,已经鉴定了一系列结构上不同的PAFR拮抗剂。 这些包括在结构上类似于天然PAF配体,合成杂环,复合多环天然产物和各种金属配合物的化合物。 本次审查提供了在该地区超过20年的进展情况的更新。 讨论了新的PAFR拮抗剂,结构 - 活性关系研究,这些分子的生物学活性的发展和合成及其治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号